Abstract
Korean cord blood banks (CBBs) are stagnant, so we explore how to overcome this. For eligible CB units (CBUs), CBBs need to strengthen quality control and conduct innovative clinical trials to facilitate cord blood transplantation (CBT). For ineligible CBUs, it is necessary to promote domestic research and remove unnecessary regulations regarding foreign research. Establishing a Korean cord blood network will facilitate communication among related groups. Now cellular immunotherapy is the new horizon for CBBs. Thus, CBBs will shift the paradigm of our mission in diverse ways.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
